Glukoza Fresenius

Glukoza Fresenius is an injectable solution that contains glucose monohydrate as its sole active ingredient. It is supplied in a sterile aqueous form for intravenous administration. The product is manufactured for the European market and is classified as a prescription‑only drug. As an excipient/solvent, it provides a readily available carbohydrate source for patients requiring parenteral nutrition, fluid replacement, or rapid correction of low blood glucose.

Glukoza Fresenius is indicated for several clinical situations where rapid carbohydrate delivery or fluid balance is needed.

- Treatment of acute hypoglycemia in patients unable to take oral glucose. - Component of parenteral nutrition regimens for patients lacking enteral intake. - Intravenous fluid and electrolyte replacement when additional carbohydrate calories are required. - Support during peri‑operative care to maintain blood glucose stability. - Dilution medium for certain intravenous medications that require a glucose‑based carrier. - Adjunct in emergency resuscitation protocols where glucose supplementation is part of the therapeutic algorithm.

Glukoza Fresenius may be associated with transient physiological changes after intravenous infusion; most reactions are mild and self‑limiting, while rare events can be clinically significant.

Common: - Mild hyperglycemia that usually resolves with routine glucose monitoring and does not require treatment. - Transient rise in serum sodium from the solution’s electrolytes, typically normalizing within a few hours. - Local irritation or erythema at the infusion site, appearing as mild redness or discomfort. - Nausea or mild headache during rapid infusion, generally subsiding after the dose is completed.

Serious: - Severe hyperglycemia that may cause osmotic diuresis and require insulin therapy. - Allergic reactions such as urticaria, angioedema, or anaphylaxis, needing immediate medical care. - Electrolyte imbalance, especially hypernatremia, when large volumes are infused rapidly, potentially leading to neurologic signs. - Fluid overload in patients with cardiac or renal impairment, which can precipitate pulmonary edema.

When using Glukoza Fresenius, clinicians should assess patient-specific factors and monitor parameters to minimize risks associated with intravenous glucose administration.

- Verify blood‑glucose level before infusion and adjust rate to avoid excessive hyperglycemia. - Assess renal and cardiac function, especially in patients at risk for fluid overload. - Use appropriate infusion sets and filter to prevent particulate contamination. - Monitor serum electrolytes, particularly sodium, during and after prolonged administration. - Document any allergic history; avoid use in patients with known hypersensitivity to glucose solutions. - Adjust infusion rate in pediatric or elderly patients, as they may have altered glucose metabolism.

Glukoza Fresenius can interact with other intravenously administered agents; awareness of potential interactions helps maintain therapeutic safety.

Avoid: - Co‑administration with high‑dose insulin infusions without glucose monitoring, which may precipitate severe hypoglycemia. - Simultaneous infusion of hypertonic saline solutions that could exacerbate hypernatremia.

Use with caution: - Concurrent use of diuretics that affect electrolyte balance; monitor sodium and fluid status closely. - Administration alongside other carbohydrate‑containing fluids, to prevent cumulative hyperglycemia. - Use in patients receiving total parenteral nutrition formulas, adjusting overall glucose load as needed. - When combined with vasopressor therapy, monitor hemodynamic response as rapid glucose shifts can influence blood pressure.